Boehringer Ingelheim GmbH Logo
2016-01-13 17:55
Boehringer Ingelheim and Arena Pharmaceuticals Collaborate to Advance Research in Schizophrenia
  • Collaboration partners to strengthen research in psychiatric diseases
    The new partnership further supports Boehringer Ingelheim’s CNS pipeline projects
    Mental diseases are an area of high unmet medical need and represent a huge economic and social burden globally
INGELHEIM, GERMANY & SAN DIEGO--(Business Wire/Korea Newswire) January 13, 2016 -- Boehringer Ingelheim and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that they have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), which belongs to the group of orphan CNS receptors. An “orphan receptor” is structurally related to a family of proteins that are known to act as functional cell-surface receptors but whose ligand has not yet been identified.

Arena will provide Boehringer Ingelheim exclusive rights to its internally discovered, novel compounds and intellectual property for an orphan CNS receptor. The companies will jointly conduct research to identify additional drug candidates that are suitable for continued research and development as therapeutic compounds for various disease indications. The agreement grants Boehringer Ingelheim exclusive worldwide rights to develop, manufacture and commercialize products resulting from the collaboration.

According to the World Health Organization, mental illness - together with substance abuse disorders - remains the leading cause of disability worldwide. At least 450 million people1 suffer from mental health problems. The global economic burden of mental illness is larger than for cancer, cardiovascular disease or diabetes and continues to grow - with significant health, social and economic consequences. As currently available treatment options leave many patients unsatisfactorily treated, more effective medicines for mental diseases are urgently needed.

“This agreement reflects our new corporate focus to enter into collaboration opportunities at various stages of development,” said Harry F. Hixson, Jr., Arena’s interim Chief Executive Officer. “Collaborations are an essential part of our drug discovery and development efforts, so we are pleased to be part of this shared goal to identify novel drugs targeting an orphan CNS receptor with Boehringer Ingelheim, who possesses demonstrated capabilities in research, development, manufacturing, and marketing of pharmaceutical products.”

“Together with our research partners in neuroscience, we are targeting brain circuits underlying major untreated symptom domains in our CNS focus areas of Alzheimer’s disease, schizophrenia, and depression. We are delighted to enter into this new collaboration with Arena, who have recognized expertise in orphan CNS GPCR drug discovery and development,” said Corporate Senior Vice President Clive R. Wood, Head of Discovery Research of Boehringer Ingelheim. “We believe that this alliance with Arena will allow us to deliver innovative, new medicines for the treatment of patients with psychiatric diseases such as schizophrenia and contribute to our vision of helping the millions of people with mental illness, to live fuller, more independent lives, for longer.”

The new partnership combines Arena’s expertise in GPCR focused drug discovery and development with Boehringer Ingelheim’s unique approach to CNS research and development and its proven capabilities in bringing novel medications of high therapeutic value to the market in areas of high unmet medical need.

The collaboration is part of Boehringer Ingelheim’s commitment to researching and developing new and more effective treatments for psychiatric diseases and their symptoms.

Under the terms of the agreement, Arena is eligible to receive payments up to $262 million in success milestones in case of full commercial success of multiple drug products, including an upfront payment and research funding. In addition, Arena is eligible to receive tiered royalties on future sales of products that arise from the collaboration. Further details of the agreement were not disclosed.

Intended audiences

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Please click on the link below for ‘Additional information’ and ‘References’:

https://www.boehringer-ingelheim.com/news/news_releases/press_releases/2016/13_january_2016_collaboration.html

View source version on businesswire.com: http://www.businesswire.com/news/home/20160113005413/en/
Boehringer Ingelheim GmbH 전체 보도자료 보기
이 뉴스는 기업·기관이 발표한 보도자료 전문입니다. 언론 매체와 블로그는 보도를 목적으로 이 보도자료를 사용할 수 있습니다. 보도자료 등록 안내
Media Contact

Boehringer Ingelheim
Dr. Reinhard Malin
Director Corporate Communications
+49 (6132) 77-90815
press@boehringer-ingelheim.com" class="link1">press@boehringer-ingelheim.com

Boehringer Ingelheim
Julia Meyer-Kleinmann
Director Corporate Communications
+49 (6132) 77-8271
press@boehringer-ingelheim.com" class="link1">press@boehringer-ingelheim.com

Arena Pharmaceuticals, Inc.
Craig M. Audet, Ph.D., Senior Vice President,
Operations and Head of Global Regulatory Affairs
caudet@arenapharm.com
858.453.7200, ext. 1612
www.arenapharm.com

이 보도자료 관련 분야

건강  제약  제휴  해외

관심 분야 보도자료 구독 방법

가입하면 관심 분야 보도자료를 마이 뉴스와 이메일로 볼 수 있습니다. 스마트폰과 RSS로도 가능합니다.

보도자료 배포 서비스 안내

뉴스와이어는 4천여개 언론매체에서 일하는 1만7천여명의 기자에 보도자료를 배포해 언론이 보도할 수 있게 합니다.

해외 보도자료 배포 안내
비즈니스와이어와 제휴해 해외 언론에 보도자료를 배포합니다.